Vivodyne — an innovative therapeutics development company that accelerates new cures to human diseases with large-scale testing on many thousands of lifelike, lab-grown human organ tissues — announced today that it has expanded its leadership team with Anthony Bahinski, Ph.D., MBA, FAHA joining as its Chief Technology Officer.
Prior to Vivodyne, Dr. Bahinski served as the Global Head of Safety Pharmacology at GlaxoSmithKline. At GlaxoSmithKline, his responsibilities were focused on coordinating a global strategy to investigate safety risks of drugs on the cardiovascular, respiratory, CNS, renal, and other specialized tissues, both in vitro and in vivo. Additionally, he was responsible for reducing the attrition of drug candidates that advanced to clinical trials, by assessing clinical translation of in vitro/ex vivo data and working in collaboration with the Drug Design and Selection Platform teams.
Dr. Bahinski maintains his ongoing participation on the FDA scientific advisory committee, as well as the NWO-AES (Dutch Research Council) SMART Organ on Chip (OoC) project Industrial Advisory Board. Before his role at GlaxoSmithKline, Dr. Bahinski spent time at Harvard’s Wyss Institute as Lead Senior Staff Scientist on the Advanced Technology Team, leading DARPA and FDA collaborative efforts in development of organ chip systems. He has over 20 years’ experience in pharmaceutical drug development including positions at Pfizer, Pharmacia, and Proctor and Gamble Pharmaceuticals.
As Vivodyne’s CTO, Dr. Bahinski will be leading the seamless translation of Vivodyne’s automated platform for massively scalable safety and efficacy testing on lifelike lab-grown human tissues to Vivodyne’s pharmaceutical and regulatory partners.
CEO Andrei Georgescu commented, “We’re absolutely thrilled to have Anthony join the team as Vivodyne’s new CTO. Anthony’s innovative mindset and experience in translating preclinical data to inform drug candidate selection for clinical trials — especially when paired with Vivodyne’s capacity to produce high-throughput, high-content preclinical human data — will accelerate Vivodyne’s efforts to revolutionize preclinical testing and decouple it from the ethical concerns, logistical bottlenecks, and underwhelming performance of animal testing.”
“The ability to screen and develop new lifesaving candidate drugs, testing thousands at a time on the functionally realistic human tissues in Vivodyne’s automated platform, represents a step-change like nothing we have seen before in the pharmaceutical industry.”
“The pharmaceutical, chemical, and cosmetics industries, as well as regulatory agencies around the world, have been waiting a decade for a solution like Vivodyne’s platform, and I cannot be more excited to drive Vivodyne’s efforts in this new role,” said Dr. Bahinski. “The ability to screen and develop new lifesaving candidate drugs, testing thousands at a time on the functionally realistic human tissues in Vivodyne’s automated platform, represents a step-change like nothing we have seen before in the pharmaceutical industry. Vivodyne’s impact and their supportive, growth-oriented culture make me excited to lead the translation of their technology in collaborations and co-developments with pharmaceutical giants to deliver patient impact that changes people’s lives.”
ABOUT VIVODYNE
Vivodyne is changing how scientists study human biology & develop therapeutics. Their platform technology creates a new preclinical drug development pipeline — Pipeline V — that starts and ends in lab-grown human tissues. The company was founded at the University of Pennsylvania by Bioengineering Ph.D. Andrei Georgescu and Associate Professor of Bioengineering Dan Huh. For more information, visit https://vivodyne.com.
